Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.19.3
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents [note 5] $ 7,375 $ 9,515
Short-term investments [note 5]   5,089
Prepaid expenses and other assets 264 933
Total current assets 7,639 15,537
Restricted cash [note 5] 50 50
Property and equipment, net 64 35
Right-of-use assets [note 7] 372  
Other assets 190 118
License agreement [note 3 and 4] 2,143 2,310
Goodwill [note 4] 1,034 1,034
Total assets 11,492 19,084
Current liabilities:    
Accounts payable 574 144
Accrued liabilities other 424 748
Accrued clinical liabilities 737 1,199
Accrued compensation 1,206 1,168
Current portion of long-term obligations [note 7] 198 11
Total current liabilities 3,139 3,270
Long-term obligations [note 7] 212 12
Total liabilities 3,351 3,282
Commitments and contingencies [note 7]
Stockholders' equity:    
Series A convertible preferred stock, $0.001 par value, 5,000,000 shares authorized, zero issued and outstanding at Sept 30, 2019 and 579 issued and outstanding at December 31, 2018.
Common stock, $0.001 par value, 150,000,000 shares authorized, 8,102,764 issued and outstanding at Sept 30, 2019 and 6,721,117 issued and outstanding at December 31, 2018, respectively. 19 18
Additional paid-in capital 50,628 41,161
Accumulated deficit (42,510) (25,381)
Accumulated other comprehensive income 4 4
Total stockholders' equity 8,141 15,802
Total liabilities and stockholders' equity $ 11,492 $ 19,084